Cancer Clinical Trial - Kymera

Cancer

Status:

Recruiting

ClinicalTrials.gov:

NCT05775406

 

This Phase 1 study will evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics (PK/PD), and clinical activity of KT-253 in adult patients with relapsed or refractory (R/R) high grade myeloid malignancies, acute lymphocytic leukemia (ALL), R/R lymphoma, and R/R solid tumors. The study will identify the pharmacologically optimal dose(s) of KT-253 as the recommended Phase 2 dose (RP2D), based on all safety, PK, PD, and efficacy data.

Drug

KT-253

Phase

Phase 1

Condition

Myeloid Malignancies Acute Lymphocytic Leukemia Lymphomas Advanced Solid Tumors